Deubiquitinase USP2a Sustains Interferons Antiviral Activity by Restricting Ubiquitination of Activated STAT1 in the Nucleus
QH301-705.5
Immunoblotting
Real-Time Polymerase Chain Reaction
Transfection
Sendai virus
Cell Line
12. Responsible consumption
03 medical and health sciences
Endopeptidases
Humans
Immunoprecipitation
Biology (General)
Cell Nucleus
0303 health sciences
Ubiquitination
Vesiculovirus
RC581-607
Flow Cytometry
Protein Transport
STAT1 Transcription Factor
Microscopy, Fluorescence
Virus Diseases
Interferons
Immunologic diseases. Allergy
Ubiquitin Thiolesterase
Research Article
Signal Transduction
DOI:
10.1371/journal.ppat.1005764
Publication Date:
2016-07-19T13:31:15Z
AUTHORS (17)
ABSTRACT
STAT1 is a critical transcription factor for regulating host antiviral defenses. STAT1 activation is largely dependent on phosphorylation at tyrosine 701 site of STAT1 (pY701-STAT1). Understanding how pY701-STAT1 is regulated by intracellular signaling remains a major challenge. Here we find that pY701-STAT1 is the major form of ubiquitinated-STAT1 induced by interferons (IFNs). While total STAT1 remains relatively stable during the early stages of IFNs signaling, pY701-STAT1 can be rapidly downregulated by the ubiquitin-proteasome system. Moreover, ubiquitinated pY701-STAT1 is located predominantly in the nucleus, and inhibiting nuclear import of pY701-STAT1 significantly blocks ubiquitination and downregulation of pY701-STAT1. Furthermore, we reveal that the deubiquitinase USP2a translocates into the nucleus and binds to pY701-STAT1, and inhibits K48-linked ubiquitination and degradation of pY701-STAT1. Importantly, USP2a sustains IFNs-induced pY701-STAT1 levels, and enhances all three classes of IFNs- mediated signaling and antiviral activity. To our knowledge, this is the first identified deubiquitinase that targets activated pY701-STAT1. These findings uncover a positive mechanism by which IFNs execute efficient antiviral signaling and function, and may provide potential targets for improving IFNs-based antiviral therapy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (40)
CITATIONS (42)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....